Downloads: 513

Files in This Item:
File Description SizeFormat 
Kanai_2010_Cancer Epidemiology.pdf265.34 kBAdobe PDFView/Open
Title: Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy.
Authors: Kanai, Masashi  kyouindb  KAKEN_id
Yoshioka, Akira
Tanaka, Shiro  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0001-6817-5235 (unconfirmed)
Nagayama, Satoshi
Matsumoto, Shigemi  kyouindb  KAKEN_id
Nishimura, Takafumi
Niimi, Miyuki
Teramukai, Satoshi
Takahashi, Ryo  kyouindb  KAKEN_id
Mori, Yukiko  kyouindb  KAKEN_id
Kitano, Toshiyuki  kyouindb  KAKEN_id
Ishiguro, Hiroshi  kyouindb  KAKEN_id
Yanagihara, Kazuhiro
Chiba, Tsutomu  kyouindb  KAKEN_id
Fukushima, Masanori
Matsuda, Fumihiko  kyouindb  KAKEN_id
Author's alias: 金井, 雅史
Keywords: Oxaliplatin
Neurotoxicity
Colorectal cancer
GSTP1 Ile105Val
AGXT Pro11Leu
AGXT Ile340Met
Issue Date: Apr-2010
Journal title: Cancer epidemiology
Volume: 34
Issue: 2
Start page: 189
End page: 193
Abstract: PURPOSE: Although the risk of oxaliplatin-induced neuropathy depends on cumulative oxaliplatin dose, susceptibility to this adverse event differs greatly among patients. In this study, we investigated the associations between oxaliplatin-induced neuropathy and the following polymorphisms: glutathione S-transferase pi (GSTP1) Ile(105)Val, and glyoxylate aminotransferase (AGXT) Pro(11)Leu and AGXT Ile(340)Met. EXPERIMENTAL DESIGN: Eighty-two Japanese patients with histologically confirmed colorectal cancer who received at least six cycles of the modified FOLFOX6 (m-FOLFOX6) regimen were enrolled. To minimize differences in cumulative oxaliplatin dose between patients, oxaliplatin-induced neuropathy was evaluated using an oxaliplatin-specific scale during the 2-week period after completion of the sixth cycle of treatment. RESULTS: Forty-four patients developed grade 2/3 oxaliplatin-induced neuropathy. There were more patients carrying at least one GSTP1(105)Val allele among the group with grade 2/3 neuropathy (18/44, 41%) than among the group with grade 1 neuropathy (9/38, 24%), although the difference was not statistically significant (P=0.098). There were similar numbers of patients carrying at least one AGXT(105)Met allele in the grade 2/3 neuropathy (7/44, 16%) and grade 1 neuropathy groups (5/38, 13%; P=0.725). The AGXT(11)Leu allele was not found in any of our patients or controls. CONCLUSIONS: We found no significant association between oxaliplatin-induced neuropathy and the GSTP1 Ile(105)Val and AGXT Ile(340)Met polymorphisms. Given that no AGXT(11)Leu allele was found among our study population (n=177), evaluating this polymorphism in Japanese patients in future studies is likely to be uninformative.
Rights: © 2010 Elsevier
この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。This is not the published version. Please cite only the published version.
URI: http://hdl.handle.net/2433/109963
DOI(Published Version): 10.1016/j.canep.2010.02.008
PubMed ID: 20308030
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.